XOMAXOMA Corp
$42.15
$0.00
(0.00%)
Pre-Market
EarningsAug 13
Mkt Cap$745.16M
Vol170,867.00
Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders?
Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders? Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 12, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...
PR Newswire
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TMHC, CZR, XOMA, and RAMP
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TMHC, CZR, XOMA, and RAMP SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TMHC, CZR, XOMA, and RAMP PR Newswire NEW YORK, June 10, 2026 NEW YORK, June 10, 2026 /PRNewswire/ -- Class...
PR Newswire
Oncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue Estimates
Oncobiologics (OTLK) delivered earnings and revenue surprises of -33.33% and -97.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders?
Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders? Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 14, 2026 Insiders may stand to receive...
PR Newswire
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates
Kyntra Bio (KYNB) delivered earnings and revenue surprises of -11.48% and +140.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Are SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders?
Are SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders? Are SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 8, 2026 Insiders may stand to...
PR Newswire
CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates
CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -23.33% and +80.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of +10.59% and -86.24%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of +64.91% and +9.64%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--HLX, OGN, XOMA, and RMAX
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--HLX, OGN, XOMA, and RMAX SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--HLX, OGN, XOMA, and RMAX PR Newswire NEW YORK, May 6, 2026 NEW YORK, May 6, 2026 /PRNewswire/ -- Class Action AttorneyJuan...
PR Newswire
<
1
2
...
>